{"id":"https://openalex.org/W2096264404","doi":null,"title":"Evolving role of novel targeted agents in renal cell carcinoma.","display_name":"Evolving role of novel targeted agents in renal cell carcinoma.","publication_year":2007,"publication_date":"2007-09-01","ids":{"openalex":"https://openalex.org/W2096264404","mag":"2096264404","pmid":"https://pubmed.ncbi.nlm.nih.gov/17926797"},"language":"en","primary_location":{"id":"pmid:17926797","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17926797","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102785664","display_name":"Thomas E. Hutson","orcid":"https://orcid.org/0000-0002-4529-4212","observed_orcids":["https://orcid.org/0000-0002-4529-4212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas E Hutson","raw_affiliation_strings":["Baylor Sammons Cancer Center, U.S. Oncology Research Network Dallas, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Sammons Cancer Center, U.S. Oncology Research Network Dallas, Texas, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050649350","display_name":"Robert A. Figlin","orcid":"https://orcid.org/0000-0002-6323-6075","observed_orcids":["https://orcid.org/0000-0002-6323-6075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert A Figlin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":6.051,"has_fulltext":false,"cited_by_count":32,"citation_normalized_percentile":{"value":0.96249833,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"21","issue":"10","first_page":"1175","last_page":"80; discussion 1184, 1187, 1190"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.9430000185966492},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9860000014305115},{"id":"https://openalex.org/keywords/hypoxia-inducible-factor","display_name":"hypoxia-inducible factor","score":0.8840000033378601},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.8690000176429749},{"id":"https://openalex.org/keywords/mtor-signaling","display_name":"mTOR signaling","score":0.6840000152587891},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":1.0},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.8859999775886536},{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":1.0},{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":0.878000020980835},{"id":"https://openalex.org/keywords/axitinib","display_name":"axitinib","score":1.0},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9670000076293945},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.7020000219345093},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.628000020980835}],"concepts":[{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.9403484463691711},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.8674689531326294},{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.8432207703590393},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.8291666507720947},{"id":"https://openalex.org/C2776539811","wikidata":"https://www.wikidata.org/wiki/Q4830631","display_name":"Axitinib","level":4,"score":0.7932010889053345},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.7408350110054016},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6411409378051758},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.6097549796104431},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6071239709854126},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6011402010917664},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.5422829389572144},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5379742980003357},{"id":"https://openalex.org/C2908861226","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib malate","level":4,"score":0.5265995264053345},{"id":"https://openalex.org/C98490376","wikidata":"https://www.wikidata.org/wiki/Q14876060","display_name":"mTORC1","level":4,"score":0.5105887055397034},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4574138820171356},{"id":"https://openalex.org/C2777921159","wikidata":"https://www.wikidata.org/wiki/Q32089","display_name":"Sirolimus","level":2,"score":0.43954014778137207},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4125206768512726},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4120578169822693},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35242703557014465},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34633684158325195},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3352048397064209},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.24724087119102478},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2404809594154358},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21384653449058533},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.1784006655216217},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.11608386039733887},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.0908014178276062},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D051795","descriptor_name":"Hypoxia-Inducible Factor 1, alpha Subunit","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051795","descriptor_name":"Hypoxia-Inducible Factor 1, alpha Subunit","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:17926797","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17926797","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:2096264404","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17926797","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7699999809265137}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1762817649","https://openalex.org/W2014404252","https://openalex.org/W2018348203","https://openalex.org/W2046507292","https://openalex.org/W2050026229","https://openalex.org/W2099259685","https://openalex.org/W2105677187","https://openalex.org/W2105984177","https://openalex.org/W2106453307","https://openalex.org/W2109896022","https://openalex.org/W2116177733","https://openalex.org/W2120129511","https://openalex.org/W2123784879","https://openalex.org/W2140765540","https://openalex.org/W2142364508","https://openalex.org/W2143813821","https://openalex.org/W2153867442","https://openalex.org/W2156408558","https://openalex.org/W2206164324","https://openalex.org/W2225151298","https://openalex.org/W2226493293","https://openalex.org/W2253554231","https://openalex.org/W2256356298","https://openalex.org/W2301603902","https://openalex.org/W2325164446","https://openalex.org/W2399474082","https://openalex.org/W3009736595"],"related_works":["https://openalex.org/W2949529108","https://openalex.org/W2944203781","https://openalex.org/W2074027443","https://openalex.org/W2470466748","https://openalex.org/W2013408555","https://openalex.org/W2414050349","https://openalex.org/W2113562909","https://openalex.org/W50109002","https://openalex.org/W99290919","https://openalex.org/W1971397741"],"abstract_inverted_index":{"The":[0],"treatment":[1],"of":[2,19,22,29,40,58,94,129],"metastatic":[3,135],"renal":[4],"cell":[5],"carcinoma":[6],"(RCC)":[7],"has":[8,24],"changed":[9],"dramatically":[10],"over":[11],"the":[12,20,27,37,45,55,127],"past":[13],"few":[14],"years.":[15],"An":[16],"improved":[17,80],"understanding":[18],"biology":[21],"RCC":[23],"resulted":[25],"in":[26,83,114],"development":[28],"novel":[30,101],"targeted":[31],"therapeutic":[32],"agents":[33,96,131],"that":[34],"have":[35,64,79],"altered":[36],"natural":[38],"history":[39],"this":[41],"disease.":[42],"In":[43],"particular,":[44],"hypoxia-inducible":[46],"factor":[47,51],"(HIF)/vascular":[48],"endothelial":[49],"growth":[50],"(VEGF)":[52],"pathway":[53,63],"and":[54,76,92,107,109,119],"mammalian":[56],"target":[57],"rapamycin":[59],"(mTOR)":[60],"signal":[61],"transduction":[62],"been":[65],"exploited.":[66],"Sunitinib":[67],"malate":[68],"(Sutent),":[69],"sorafenib":[70],"tosylate":[71],"(Nexavar),":[72],"bevacizumab":[73],"(Avastin)/interferon":[74],"alfa,":[75],"temsirolimus":[77],"(Torisel)":[78],"clinical":[81,115,121],"outcomes":[82],"randomized":[84],"trials":[85,122],"by":[86],"inhibiting":[87],"these":[88,95,130],"tumorigenic":[89],"pathways.":[90],"Combinations":[91],"sequences":[93],"are":[97,113],"being":[98],"evaluated.":[99],"Other":[100],"multitargeted":[102],"tyrosine":[103],"kinase":[104],"inhibitors":[105,111],"(pazopanib":[106],"axitinib)":[108],"mTOR":[110],"(everolimus)":[112],"development.":[116],"Recently":[117],"reported":[118],"ongoing":[120],"will":[123],"help":[124],"further":[125],"define":[126],"role":[128],"as":[132],"therapy":[133],"for":[134],"RCC.":[136]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}